The FINANCIAL — Boehringer Ingelheim on September 28 announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO ...
LONDON (Reuters) - A major study on the safety of a mist inhaler used to treat chronic lung disease has found it does not increase the risk of patients dying early, in contrast to an earlier analysis ...
Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A posthoc analysis from OTEMTO® 1&2 indicates that ...
WASHINGTON (Reuters) - The lung drug Spiriva, marketed by Pfizer Inc and Boehringer Ingelheim Pharmaceutical Inc, may increase the risk of stroke, the U.S. Food and Drug Administration said on Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results